SAN DIEGO -- AmpliPhi Biosciences Corporation (APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced it has dosed the first patient in its Phase 1 clinical trial to evaluate the safety of AB-SA01, AmpliPhi’s proprietary phage cocktail targeting Staphylococcus aureus (S. aureus) infections, administered topically to the intact skin of healthy adults. The trial is being conducted under a Collaborative Research and Development Agreement with the U.S. Army and at the Walter Reed Army Institute of Research Clinical Trials Center in Silver Spring, Maryland.

 

S. aureus is a leading cause of skin and soft tissue infections, especially among individuals with underlying health conditions. Despite vigorous eradication efforts, S. aureus is common in hospitals where it can plague patients with weakened immune systems, burns and surgical wounds.

Acquisition expands neurology product portfolio

Enhances sales infrastructure

 

ATLANTA & SANTA CLARA, Calif.--- Arbor Pharmaceuticals, LLC (Arbor) and XenoPort, Inc. (XenoPort) (XNPT) announced today that they have signed a definitive agreement under which Arbor will acquire XenoPort for $7.03 per share in cash, or a total equity value of approximately $467 million. The purchase price per share represents a 60 percent premium to the closing price of XenoPort shares on May 20, 2016.

 

This Smart News Release features multimedia. View the full release here:http://www.businesswire.com/news/home/20160523005513/en/

 

“We are pleased to be adding HORIZANT and the XenoPort pipeline to the growing portfolio of Arbor products,” said Ed Schutter, President and Chief Executive Officer of Arbor. “We believe that XenoPort’s lead product HORIZANT offers patients and physicians a valuable treatment option for moderate-to-severe primary restless legs syndrome and postherpetic neuralgia. The XenoPort sales team has done an excellent job of growing HORIZANT, and we look forward to supporting them to continue this significant momentum.”

--REOLYSIN® Demonstrates Increase in Objective Response Rates in Female Patients  and in Patients with Liver Metastases--

 

CALGARY, May 19, 2016 Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC.TO - News) (OTCQX:ONCYF) (FRA:ONY.F - News) today announced preliminary data from a randomized Phase II clinical trial of its lead product, REOLYSIN®, in combination with FOLFOX-6 and bevacizumab (Avastin®) in patients with advanced or metastatic colorectal cancer (IND 210). The study is being sponsored by the National Cancer Institute of Canada ("NCIC") Clinical Trials Group ("CTG") at Queen's University in Kingston, Ontario. The preliminary analysis includes data from an NCIC study summary report, and follows the release of an abstract to be presented at the American Society of Clinical Oncology ("ASCO") Annual Meeting, which will run from June 3-7, 2016 in Chicago, IL.

Patent Further Supports the Company’s Phospholipid Drug Conjugate (PDC) Platform and Provides Intellectual Property Protection for Chemotherapeutic Drug Conjugates to November 2036

 

MADISON, Wis., May 20, 2016  -- Cellectar Biosciences, Inc. (CLRB) (the Company), an oncology-focused biotechnology company, today announces that its previously filed non-provisional US and International (PCT) patent applications for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles have received their US Patent and Trademark Office (USPTO) identification numbers and have been published by the USPTO, which marks the next step in the application process for approval and issuance of these patents.

 

As previously stated, these patents will protect both composition of matter and method of use for those phospholipid drug conjugates, or PDCs, developed with Cellectar’s proprietary phospholipid-ether delivery vehicle conjugated with any existing or future cytotoxic agents, including chemotherapeutics such as paclitaxel, for targeted delivery to cancer cells and cancer stem cells.